Literature DB >> 23180183

MM2 subtype of sporadic Creutzfeldt-Jakob disease may underlie the clinical presentation of progressive supranuclear palsy.

Igor N Petrovic1, Antonio Martin-Bastida, Luke Massey, Helen Ling, Sean S O'Sullivan, David R Williams, Janice L Holton, Tamas Revesz, James W Ironside, Andrew J Lees, Laura Silveira-Moriyama.   

Abstract

The classical presentation of sporadic Creutzfeldt-Jakob disease (sCJD) is rapid progressive dementia often associated with myoclonus and ataxia followed by death in less than a year from diagnosis. The few patients in the literature who presented with parkinsonism and who were suspected to have progressive supranuclear palsy (PSP) all ran a malignant course and most of them died within 3 years of diagnosis. We screened the Queen Square Brain Bank database and, among 213 patients with a clinical diagnosis of PSP, we found ten patients with 3 years or less disease duration, including one patient with CJD pathology. We report this patient and review other similar cases from the literature. Ten additional cases with similar presentation were identified in the literature. The mean disease duration was 24.2 months. The classical clinical, radiological and laboratory findings for sCJD were absent in the majority of these cases. Clinical presentation of these patients consists of: early falls, prominent dementia, early vertical supranuclear gaze palsy and symmetric akinetic syndrome. In the patients who were subtyped at post-mortem, all four represented the MM2 subtype of sCJD. A rapidly progressive course of PSP with early falls, cognitive impairments and vertical supranuclear gaze palsy should raise suspicion of underlying sCJD pathology regardless of absence of supportive findings on ancillary tests. This case and the literature support the notion that biochemical properties of the prion protein can influence the clinical presentation of sCJD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23180183     DOI: 10.1007/s00415-012-6752-7

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  18 in total

1.  Characterizing behavioral and cognitive dysexecutive changes in progressive supranuclear palsy.

Authors:  David Millar; Philipa Griffiths; Adam J Zermansky; David J Burn
Journal:  Mov Disord       Date:  2006-02       Impact factor: 10.338

2.  A case of progressive subcortical gliosis associated with deposition of abnormal prion protein (PrP)

Authors:  T Revesz; S E Daniel; A J Lees; R G Will
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-06       Impact factor: 10.154

Review 3.  Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop.

Authors:  I Litvan; Y Agid; D Calne; G Campbell; B Dubois; R C Duvoisin; C G Goetz; L I Golbe; J Grafman; J H Growdon; M Hallett; J Jankovic; N P Quinn; E Tolosa; D S Zee
Journal:  Neurology       Date:  1996-07       Impact factor: 9.910

4.  Novel prion protein gene mutation presenting with subacute PSP-like syndrome.

Authors:  D B Rowe; V Lewis; M Needham; M Rodriguez; A Boyd; C McLean; H Roberts; C L Masters; S J Collins
Journal:  Neurology       Date:  2007-03-13       Impact factor: 9.910

5.  Thalamic form of Creutzfeldt-Jakob disease or fatal insomnia? Report of a sporadic case with normal prion protein genotype.

Authors:  K Kawasaki; K Wakabayashi; A Kawakami; M Higuchi; T Kitamoto; S Tsuji; H Takahashi
Journal:  Acta Neuropathol       Date:  1997-03       Impact factor: 17.088

6.  Supranuclear vertical gaze abnormalities in sporadic Creutzfeldt-Jakob disease.

Authors:  Sashank Prasad; Melissa W Ko; Edward B Lee; Nicholas K Gonatas; Matthew B Stern; Steven Galetta
Journal:  J Neurol Sci       Date:  2007-01-17       Impact factor: 3.181

7.  Creutzfeldt-Jakob disease presenting as progressive supranuclear palsy.

Authors:  K A Josephs; Y Tsuboi; D W Dickson
Journal:  Eur J Neurol       Date:  2004-05       Impact factor: 6.089

8.  Diagnostic accuracy of progressive supranuclear palsy in the Society for Progressive Supranuclear Palsy brain bank.

Authors:  Keith A Josephs; Dennis W Dickson
Journal:  Mov Disord       Date:  2003-09       Impact factor: 10.338

9.  A unique case of sporadic Creutzfeldt-Jacob disease presenting as progressive supranuclear palsy.

Authors:  Munehisa Shimamura; Eiichiro Uyama; Teruyuki Hirano; Tatsuhumi Murakami; Shuji Mita; Tetsuyuki Kitamoto; Makoto Uchino
Journal:  Intern Med       Date:  2003-02       Impact factor: 1.271

10.  Creutzfeldt-Jakob disease with slow progression. A mimickry of progressive supranuclear palsy.

Authors:  F M Huber; F Bour; V Sazdovitch; J J Hauw; U Heinemann; F Zanini; D W Droste; N J Diederich
Journal:  Bull Soc Sci Med Grand Duche Luxemb       Date:  2007
View more
  7 in total

1.  Supranuclear gaze palsy and horizontal ocular oscillations in Creutzfeldt-Jakob disease.

Authors:  Asya I Wallach; Hannah Park; Janet C Rucker; Horacio Kaufmann
Journal:  Neurology       Date:  2017-08-15       Impact factor: 9.910

Review 2.  Neurological update: dementia.

Authors:  A J Larner
Journal:  J Neurol       Date:  2014-02-06       Impact factor: 4.849

3.  Sporadic Fatal Insomnia Presenting with Initial Symptoms of Parkinsonism and Abnormal Dopamine Transporter Imaging.

Authors:  Tatevik Mkhitarjan; Aušrinė Areškevičiūtė; Eva Løbner Lund; Lisbeth Marner; Anne-Mette Hejl
Journal:  Mov Disord Clin Pract       Date:  2021-12-27

Review 4.  The diagnostic value of saccades in movement disorder patients: a practical guide and review.

Authors:  Pichet Termsarasab; Thananan Thammongkolchai; Janet C Rucker; Steven J Frucht
Journal:  J Clin Mov Disord       Date:  2015-10-15

Review 5.  Clinical Approach to Supranuclear Brainstem Saccadic Gaze Palsies.

Authors:  Alexandra Lloyd-Smith Sequeira; John-Ross Rizzo; Janet C Rucker
Journal:  Front Neurol       Date:  2017-08-23       Impact factor: 4.003

Review 6.  Clinical Approach to Progressive Supranuclear Palsy.

Authors:  Helen Ling
Journal:  J Mov Disord       Date:  2016-01-25

7.  Fulminant corticobasal degeneration: a distinct variant with predominant neuronal tau aggregates.

Authors:  Helen Ling; Ellen Gelpi; Karen Davey; Zane Jaunmuktane; Kin Y Mok; Edwin Jabbari; Roberto Simone; Lea R'Bibo; Sebastian Brandner; Matthew J Ellis; Johannes Attems; David Mann; Glenda M Halliday; S Al-Sarraj; J Hedreen; James W Ironside; Gabor G Kovacs; E Kovari; S Love; Jean Paul G Vonsattel; Kieren S J Allinson; Daniela Hansen; Teisha Bradshaw; Núria Setó-Salvia; Selina Wray; Rohan de Silva; Huw R Morris; Thomas T Warner; John Hardy; Janice L Holton; Tamas Revesz
Journal:  Acta Neuropathol       Date:  2020-01-16       Impact factor: 17.088

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.